Anti-obesity Effects of Dandelion (Taraxacum Officinale L.) in Premenopausal Obese Women: Impacts on Appetite, Energy Intake and Lipid Metabolism
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 120
- 试验地点
- 1
- 主要终点
- Changes in body weight
研究概览
简要总结
The study investigates the effectiveness of the natural product Dandelion in treating obesity in premenopausal women through a randomized interventional trial, measuring various parameters and biomarkers.
详细描述
The study aims to explore the anti-obesity effects of dandelion supplementation in premenopausal obese women. The research will measure changes in appetite, energy intake, body weight, composition, lipid profile, and inflammatory markers, providing evidence of dandelion's efficacy as an anti-obesity phototherapy. The randomized interventional trial will measure multiple parameters and biomarkers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Premenopausal women with obesity. Age between 18-45 years Stable body weight in the past 3 months
排除标准
- •Pregnancy Breastfeeding Diabetes Cardiovascular diseases kidney or liver diseases use of medications that affect body weight Smoking Allergy to dandelion or related plants
研究组 & 干预措施
Control group
The Xenical group:60 patients will receive identical capsules of 120mg (one capsule) to be taken three times daily with meals and for 12 weeks, equaling 360mg total daily dose.
干预措施: Xenical (Drug)
The dandelion extract group
The dandelion extract group: 60 patients will receive 500 mg capsules of dandelion leaf extract, given 3 times per day before meals and for 12 weeks.
干预措施: The dandelion extract (Dietary Supplement)
结局指标
主要结局
Changes in body weight
时间窗: monthly change, assessed up to 3 months
Change in fat mass
时间窗: Monthly change, assessed up to 3 months
次要结局
- Appetite Ratings(monthly change, assessed up to 3 months)
- Dietary intake via 24-hour recalls(Recorded for patients daily, assessed up to 3 months)
- Lipid profile(Monthly change, assessed up to 3 months)
- CRP(Monthly change, assessed up to 3 months)
- TNF-α(Monthly change, assessed up to 3 months)
- IL-6(Monthly change, assessed up to 3 months)
- IL-16(Monthly change, assessed up to 3 months)
- Glycemic indices(Monthly change, assessed up to 3 months)
研究者
rabab ahmed mohamed
Principle investigator
October 6 University